FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 478 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas January 20, 2021 Cancer Research UK reports record levels of investment in its spinouts August 24, 2021 Firefighter Advocates For Men’s Health While He Battles Breast Cancer In... September 22, 2021 Artificial Intelligence Expedites Brain Tumor Diagnosis during Surgery February 12, 2020 Load more HOT NEWS How to Stay Connected When Your Partner Has Cancer Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with...
